Antibodies News and Research

RSS

Discovery provides clues for potentially eliminating HIV infection in children

A two-year-old child born with HIV infection and treated with antiretroviral drugs beginning in the first days of life no longer has detectable levels of virus using conventional testing despite not taking HIV medication for 10 months, according to findings presented today at the Conference on Retroviruses and Opportunistic Infections in Atlanta.

5 Mar 2013

Study highlights long-term benefits of early antiretroviral therapy initiated in infants

A study led by University of Massachusetts Medical School professor and immunologist Katherine Luzuriaga, MD, and Johns Hopkins Children's Center virologist Deborah Persaud, MD, highlights the long-term benefits of early antiretroviral therapy (ART) initiated in infants.

5 Mar 2013

Study finds how to shut down Bcl6 in diffuse large B-cell lymphoma

The powerful master regulatory transcription factor called Bcl6 is key to the survival of a majority of aggressive lymphomas, which arise from the B-cells of the immune system. The protein has long been considered too complex to target with a drug since it is also crucial to the healthy functioning of many immune cells in the body, not just B cells gone bad.

4 Mar 2013

Prompt antiretroviral therapy may help infants clear the HIV and achieve long-term remission

A team of researchers from Johns Hopkins Children's Center, the University of Mississippi Medical Center and the University of Massachusetts Medical School describe the first case of a so-called "functional cure" in an HIV-infected infant. The finding, the investigators say, may help pave the way to eliminating HIV infection in children.

4 Mar 2013

Global inhibition of all Notch signals would not be safe after bone marrow transplantation

Bone marrow transplant is a key treatment for patients with leukemia, lymphoma, multiple myeloma and other blood disorders. University of Michigan researchers have discovered that inhibiting a signaling pathway in some of the transplanted cells could prevent the most serious potential complications of the procedure, a conflict between the transplanted cells and the recipient's own tissue called graft-versus-host disease.

2 Mar 2013

Melanoma tumours deliberately create conditions that knock out body's premier immune defence

New research in the Journal of Clinical Investigation reveals that tumours in melanoma patients deliberately create conditions that knock out the body's 'premier' immune defence and instead attract a weaker immune response unable to kill off the tumour's cancerous cells.

2 Mar 2013

Synthetic progesterone birth control injections have vulnerability to certain infections: Research

Women who are pregnant or using synthetic progesterone birth control injections have a conspicuous vulnerability to certain infections including malaria, Listeria, HIV, and herpes simplex virus.

2 Mar 2013

Exposure to BPA may increase risk of asthma in young children

Researchers at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health are the first to report an association between early childhood exposure to the chemical bisphenol A (BPA) and an elevated risk for asthma in young children. BPA is a component of some plastics and is found in food can liners and store receipts.

1 Mar 2013

Anti-LG3 associated with high rate of organ rejection during transplantation

A team led by Dr. Marie-Jos-e H-bert from the University of Montreal Hospital* Research Centre (CRCHUM) has discovered a new cause of organ rejection in some kidney transplant patients. Her team has identified a new class of antibodies - anti-LG3 - which when activated lead to severe rejection episodes associated with a high rate of organ loss.

28 Feb 2013

Engineering chemotherapy drugs' shape increases their ability to target and inhibit cancer cells

Bioengineering researchers at University of California, Santa Barbara have found that changing the shape of chemotherapy drug nanoparticles from spherical to rod-shaped made them up to 10,000 times more effective at specifically targeting and delivering anti-cancer drugs to breast cancer cells.

28 Feb 2013

MenB bacterium uses Adhesin Complex Protein to stick to human cells

Scientists at the University of Southampton have taken a significant and important step in keeping people safe from the most common form of meningitis in the UK.

28 Feb 2013

XBiotech to enter biosimilar business

XBiotech, a privately held biotechnology company, announced today that it is entering the biosimilar business. The Company is launching its biosimilar business with development of two of the world's leading therapeutic antibodies, one an oncology and the other an anti-inflammatory product.

26 Feb 2013

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.

From Baxter International Inc. 26 Feb 2013

Natalizumab may be second-line option for pediatric MS patients

Natalizumab may be an effective and well tolerated second-line treatment for pediatric patients with highly active relapsing-remitting multiple sclerosis, say researchers.

26 Feb 2013

Researchers improve NanoVelcro device to better grab cancer cells as blood passes by them

Researchers at UCLA report that they have refined a method they previously developed for capturing and analyzing cancer cells that break away from patients' tumors and circulate in the blood. With the improvements to their device, which uses a Velcro-like nanoscale technology, they can now detect and isolate single cancer cells from patient blood samples for analysis.

26 Feb 2013

Protamine–heparin complex antibodies raise concerns

Almost a third of patients treated with protamine for heparin reversal during cardiopulmonary bypass develop antibodies to circulating protamine–heparin complexes, study findings suggest.

25 Feb 2013

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.

25 Feb 2013

Antibodies News and Research

Discovery provides clues for potentially eliminating HIV infection in children

Study highlights long-term benefits of early antiretroviral therapy initiated in infants

Study finds how to shut down Bcl6 in diffuse large B-cell lymphoma

Prompt antiretroviral therapy may help infants clear the HIV and achieve long-term remission

Global inhibition of all Notch signals would not be safe after bone marrow transplantation

Melanoma tumours deliberately create conditions that knock out body's premier immune defence

Synthetic progesterone birth control injections have vulnerability to certain infections: Research

Exposure to BPA may increase risk of asthma in young children

Anti-LG3 associated with high rate of organ rejection during transplantation

Engineering chemotherapy drugs' shape increases their ability to target and inhibit cancer cells

MenB bacterium uses Adhesin Complex Protein to stick to human cells

XBiotech to enter biosimilar business

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Natalizumab may be second-line option for pediatric MS patients

Researchers improve NanoVelcro device to better grab cancer cells as blood passes by them

Protamine–heparin complex antibodies raise concerns

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

Two USC scientists develop new algorithm to help predict value of DNA sequencing

Antibody delivery system launched that works even in presence of additives

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

Antibodies eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News